Data from phase 3 trials of the drug in diabetic macular oedema (DMO) provide some encouragement ... when it came to inflammatory reactions in the eye. Earlier this year, Novartis halted three ...
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback